Johnson & Johnson (JNJ) Stock Forecast & Price Target

$146.19 -0.22 (-0.15%)

(As of 09:46 AM ET)

Johnson & Johnson - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 14 Analyst Ratings

Sell
0

Hold
7

Buy
7

Based on 14 Wall Street analysts who have issued ratings for Johnson & Johnson in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 7 have given a hold rating, and 7 have given a buy rating for JNJ.

Consensus Price Target

$174.73
19.52% Upside

According to the 14 analysts' twelve-month price targets for Johnson & Johnson, the average price target is $174.73. The highest price target for JNJ is $215.00, while the lowest price target for JNJ is $150.00. The average price target represents a forecasted upside of 19.52% from the current price of $146.19.

Get the Latest News and Ratings for JNJ and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Johnson & Johnson and its competitors.

JNJ Analyst Ratings Over Time

Type	Current Forecast 12/19/23 to 12/18/24	1 Month Ago 11/19/23 to 11/18/24	3 Months Ago 9/20/23 to 9/19/24	1 Year Ago 12/19/22 to 12/19/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	8 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)
Hold	7 Hold rating(s)	7 Hold rating(s)	7 Hold rating(s)	8 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$174.73	$175.94	$173.21	$168.75
Forecasted Upside	19.52% Upside	13.68% Upside	5.09% Upside	7.86% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Hold	Hold

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

JNJ Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

JNJ Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Johnson & Johnson Stock vs. The Competition

Type	Johnson & Johnson	Medical Companies	S&P 500
Consensus Rating Score	2.50	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	19.36% Upside	28,675.54% Upside	12.02% Upside
News Sentiment Rating	Positive News See Recent JNJ News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/11/2024	Citigroup 3 of 5 stars		Lower Target	Buy ➝ Buy	$185.00 ➝ $175.00	+19.18%
12/10/2024	Bank of America 3 of 5 stars		Reiterated Rating	Neutral	$166.00	+10.96%
11/15/2024	Wolfe Research 3 of 5 stars	A. Hammond Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$190.00	+25.12%
11/6/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$156.00 ➝ $162.00	+2.40%
10/16/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$215.00 ➝ $215.00	+30.70%
10/16/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$163.00 ➝ $166.00	+0.91%
Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad) Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it. Click here to watch this demo and decide for yourself.
10/16/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$178.00 ➝ $181.00	+10.28%
10/16/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$169.00 ➝ $175.00	+6.62%
7/23/2024	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Nakagiri Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/23/2024	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral	$160.00 ➝ $150.00	-2.75%
7/19/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$160.00 ➝ $155.00	+0.27%
7/18/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$161.00 ➝ $171.00	+9.10%
7/18/2024	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$195.00 ➝ $185.00	+18.03%
7/18/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$195.00 ➝ $185.00	+18.38%
4/18/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$169.00 ➝ $170.00	+17.43%
1/3/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$172.00 ➝ $175.00	+8.93%
12/1/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$167.00 ➝ $180.00	+16.39%
10/12/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$158.00 ➝ $162.00	+3.73%
8/4/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$167.00 ➝ $170.00	-0.42%
7/21/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral	$175.00 ➝ $180.00	+5.75%
7/21/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$165.00 ➝ $175.00	+3.92%
7/21/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral	$170.00 ➝ $175.00	+3.92%
2/6/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$55.00 ➝ $52.00	-68.17%
1/20/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$194.00 ➝ $186.00	+9.72%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:03 AM ET.

Should I Buy Johnson & Johnson Stock? JNJ Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, December 15, 2024. Please send any questions or comments about these Johnson & Johnson pros and cons to contact@marketbeat.com.

Johnson & Johnson
Bull Case

Here are some ways that investors could benefit from investing in Johnson & Johnson:

Johnson & Johnson has a strong market capitalization of $352.07 billion, indicating its stability and ability to weather market fluctuations.
The company recently reported earnings of $2.42 per share, exceeding analysts' expectations, which reflects its robust financial health and operational efficiency.
With a current stock price of $146.23, investors may find it an attractive entry point, especially considering the company's historical performance and growth potential.
Johnson & Johnson has a consistent dividend payout, recently declaring a quarterly dividend of $1.24 per share, which translates to an annual yield of 3.39%. This can provide a steady income stream for investors.
The company has a diverse product portfolio in the healthcare sector, which includes innovative products that cater to various consumer needs, enhancing its growth prospects.

Johnson & Johnson
Bear Case

Investors should be bearish about investing in Johnson & Johnson for these reasons:

The stock has experienced volatility, with a one-year low of $143.13, which may raise concerns about its short-term performance.
Johnson & Johnson's price-to-earnings (P/E) ratio of 21.28 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
Recent insider trading activity, such as the purchase of 1,000 shares by a director, while positive, may also indicate that insiders are taking advantage of current prices, which could be a red flag for some investors.
The company faces ongoing litigation risks related to its products, which could impact its reputation and financial performance in the long run.
With a debt-to-equity ratio of 0.45, while manageable, it indicates that the company does carry some debt, which could be a concern if interest rates rise or if the company faces financial challenges.

JNJ Forecast - Frequently Asked Questions

: According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Johnson & Johnson is $174.73, with a high forecast of $215.00 and a low forecast of $150.00.
: 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 7 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" JNJ shares.
: According to analysts, Johnson & Johnson's stock has a predicted upside of 19.52% based on their 12-month stock forecasts.
: Johnson & Johnson has been rated by research analysts at Bank of America, Cantor Fitzgerald, Citigroup, Guggenheim, Morgan Stanley, Royal Bank of Canada, Wells Fargo & Company, and Wolfe Research in the past 90 days.
: Analysts like Johnson & Johnson less than other "medical" companies. The consensus rating score for Johnson & Johnson is 2.50 while the average consensus rating score for "medical" companies is 2.81. Learn more on how JNJ compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Will the Nasdaq 100 crash? (Ad)

In a world where some top money managers say you should “diversify” with a basket of stocks to help lower risk in your portfolio… And others say you should focus on only one ticker at a time because you can’t really keep detailed tabs on 10, 20 or more stocks at once… My #1 strategy to play the Nasdaq bull run has shown the power to provide the best of BOTH worlds at the same time. Because it harnesses ONE ticker that bottles up all the firepower of Apple, Nvidia, Tesla and more into one place… While I cannot promise future returns or against losses… This strategy targets major payouts OVERNIGHT!

Click here to get the details.

This page (NYSE:JNJ) was last updated on 12/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Johnson & Johnson (JNJ) Stock Forecast & Price Target